HeartBeam Closes $10M Public Offering to Fund Commercialization of ECG Technology
HeartBeam raised $10 million in a public offering to advance its FDA-cleared 12-lead synthesized ECG system and heart attack detection technologies, positioning the company for expanded market reach.
HeartBeam (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses. The transaction, completed on April 16, 2026, was supported by key stakeholders including ClearCardio(TM), company leadership and institutional investors. The funds will be used to accelerate commercialization of HeartBeam's FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of AI capabilities and for general corporate purposes.
The offering underscores investor confidence in HeartBeam's platform technology, which aims to transform cardiac care by enabling portable, cable-free ECG monitoring. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis in December 2025. With over 20 issued patents, HeartBeam is creating the first-ever device capable of collecting ECG signals in three non-coplanar directions and synthesizing them into a 12-lead ECG. This allows physicians to identify cardiac health trends and acute conditions outside of medical facilities, potentially redefining cardiac health management.
The timing of the capital raise is critical as HeartBeam moves to commercialize its products and expand its AI capabilities. The extended-wear patch and heart attack detection technologies represent significant advancements in continuous monitoring and early intervention. By securing $10 million, the company can scale manufacturing, enhance sales and marketing efforts, and pursue further regulatory clearances. The participation of institutional investors and ClearCardio signals strong market validation for HeartBeam's approach to non-invasive cardiac diagnostics.
For more details on the offering, see the full press release at https://ibn.fm/9iNYY. Updates on HeartBeam are available in the company's newsroom at https://ibn.fm/BEAT.
Forward-looking statements in this article involve risks and uncertainties. Factors that could cause actual results to differ are discussed in HeartBeam's filings with the SEC, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.